1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

Teva Has Nasal Naloxone Nod For First US Narcan Rival

 
• By Dave Wallace

Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.

Narcan
Teva Has Approval For A Generic Version Of Narcan Nasal Spray • Source: Shutterstock

Teva’s naloxone hydrochloride nasal spray has become the first generic version of Adapt Pharma’s Narcan to receive final US Food and Drug Administration approval, following the expiry of a 30-month stay linked to ongoing patent litigation over the opioid overdose treatment. A tentative approval had been granted in June 2018.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation